Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 30 May 2018
At a glance
- Drugs Allogeneic-gamma-delta-T-cell-therapy (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 22 May 2018 Status changed from planning to not yet recruiting.
- 07 May 2018 According to an Incysus Therapeutics media release, Incysus changed its name to Incysus Therapeutics.
- 20 Mar 2018 According to an Incysus media release, trial design will be presented at the 2018 CAR-T Congress USA Meeting.